Recurrence of glioma, especially high-grade glioblastoma, is almost inevitable after surgery. Current treatments for high-grade glioblastoma are mainly surgical resection, followed by simultaneous radiotherapy and later adjuvant chemotherapy with temozolomide, and now tumor electric field therapy. Of course, patients can also choose to participate in clinical research programs that are appropriate for them and try newer treatments based on the characteristics of their tumor. Regardless of which treatment method is used, the patient’s main concern when hesitating to adopt these latest treatments is whether the method is useful for his or her condition. For the methods that are already in use in the clinic, the safety and effectiveness of these methods have been verified, and many of them have been compared with clinical trials, proving that these methods are indeed useful for the treatment of glioblastoma and can prolong the survival time before they are finally incorporated into the treatment guidelines and applied in the clinic, such as simultaneous radiotherapy and chemotherapy protocols for glioblastoma, and tumor electric field treatment protocols, and so on. However, because of the individual variability of patients, the effect of these treatments for each patient is not the same size, so that the use of the same treatment program for glioblastoma, the final survival time varies greatly. Some people with long survival times feel that these treatments are effective for them, while others with shorter survival times feel that they are not effective. For many of the newest treatments or medications that are still in clinical trials, depending on the purpose of the clinical trial, some are estimated to be effective, tested for tolerated dosage of the drug, or further validated to be effective. Of course, after validation, some are proven to be effective and may later be incorporated into clinical guidelines for routine treatment of glioblastoma. Some may end up proving to be less useful for glioblastoma and end up not being used in the treatment of glioblastoma. Of course, it’s also possible that it might work for some patients and not work for others, and could be used in the treatment of some glioblastoma patients. So, some of the glioblastoma patients who participate in the clinical trial program could benefit from it and live longer. However, regardless of which treatment is used, individual-to-individual comparisons are difficult to achieve and meaningless because of individual differences in patients. It is not at all surprising to see that some patients with glioblastoma who have only undergone surgery without subsequent adjuvant treatment such as radiotherapy survive longer than those who have undergone regular radiotherapy after surgery. To put it in another way, patients with relatively long survival time after surgery without radiotherapy may survive longer if they also choose standard radiotherapy regimen, while patients with shorter survival time after surgery with regular radiotherapy will have shorter survival time if they do not undergo surgery and radiotherapy.